Immedica
Immedica is a Stockholm-based, KKR/Impilo-owned pharmaceutical company that commercializes proprietary, in-licensed and acquired medicines for rare diseases and specialty care across 50+ countries in Europe, MENA, the U.S. and Asia.
- Company typePrivate
- Founded2018
- HeadquartersStockholm, Sweden
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immedica does
Immedica Pharma AB is a Stockholm-headquartered, privately held pharmaceutical company founded in 2018 that commercializes medicines for rare diseases and specialty care across more than 50 countries via wholly-owned subsidiaries in Europe, the Middle East and North Africa, and, since September 2024, a U.S. commercial hub in Chicago. The company is jointly owned by KKR-managed investment funds and Nordic healthcare investor Impilo AB following a September 2024 acquisition financed in part by a €320 million Hayfin-co-led single-asset continuation fund, and is led by CEO Anders Edvell with a senior team drawn heavily from Sobi/Swedish Orphan Biovitrum and other large-pharma rare-disease organizations.
The commercial portfolio is organized into four core therapeutic areas (RARE Metabolic, RARE Hematology & Oncology, RARE Neurology, RARE Endocrinology) plus Specialty Care and is assembled through a mix of proprietary biologics, in-licensing and acquisitions rather than in-house drug discovery. Flagship proprietary/lead assets include Loargys (pegzilarginase), the first and only disease-modifying treatment for Arginase 1 Deficiency with FDA accelerated approval in February 2026 and EU marketing authorization since December 2023; Ztalmy (ganaxolone), the first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder, acquired via the $151 million Marinus Pharmaceuticals takeover in January 2025; Zepzelca (lurbinectedin) for small cell lung cancer; and Efmody and Alkindi (modified-release and oral-granule hydrocortisone) for adrenal insufficiency and congenital adrenal hyperplasia, acquired via the $65 million Neurocrine/Diurnal deal in January 2026. Supporting products include Ravicti, Ammonaps and Orphacol for urea cycle disorders, Neofordex, Akynzeo, Aloxi and Yondelis, alongside a CE-marked in vitro diagnostic (Nor-NOHA Blood Collection Tubes) that anchors ARG1-D diagnosis.
Immedica generates revenue primarily through direct commercialization of proprietary and in-licensed pharmaceutical products, supplemented by royalty streams (notably a $7 million ganaxolone royalty buy-back from Ovid Therapeutics in June 2025) and exclusive distribution agreements with regional partners such as PharmaMar (Zepzelca), OrphanPacific (Ravicti in Japan), Innovative Medicines Group (Loargys in Latin America) and WinHealth (China). Pricing is not publicly disclosed and is negotiated country-by-country with national reimbursement authorities (G-BA in Germany, NICE in the UK, MENA regulators), with U.S. distribution for Loargys routed through specialty pharmacy partner Orsini. Since 2018, Immedica has executed 16 strategic transactions, scaled from 7 to more than 140 employees, and reported FY2023 net sales of SEK 905 million (~USD 85 million) at a 66% gross margin, with annual revenue growth cited above 50% at the time of the 2024 KKR acquisition.
Immedica firmographics
Firmographics- Name
- Immedica
- Legal name
- Immedica Pharma AB
- Website
- https://immedica.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Immedica is a Stockholm-based, KKR/Impilo-owned pharmaceutical company that commercializes proprietary, in-licensed and acquired medicines for rare diseases and specialty care across 50+ countries in Europe, MENA, the U.S. and Asia.
- Ownership category
- akta.pro rank
Immedica industry classification
Industry- Product category
- Specialty Pharmaceuticals (Rare Disease)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Medical and Diagnostic Laboratories (62151), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH)
Keywords
Where Immedica is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices13 records
Markets served
Immedica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical Product Sales (Commercialization): Immedica generates revenue through the commercialization and direct sales of proprietary and in-licensed rare disease and specialty care pharmaceutical products across more than 50 countries, including Loargys, Ztalmy, Efmody, Alkindi, Ravicti, Zepzelca, Ammonaps, Orphacol, Akynzeo, Aloxi, Neofordex and Yondelis.
- Royalty Acquisitions / Royalty Income: Immedica purchased future ganaxolone royalty rights from Ovid Therapeutics for $7M, allowing it to capture royalty streams on Ztalmy revenues.
- In-licensing & Distribution Agreements: Immedica earns revenue through in-licensing and exclusive distribution deals where it commercializes third-party products in its geographies (e.g., Zepzelca partnership with PharmaMar, Ravicti in Japan with OrphanPacific, Loargys in Latin America with Innovative Medicines Group).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Not publicly disclosed; quote-based / reimbursement negotiated by country |
Go-to-market motion1 record
Distribution channels4 records
Immedica product offering
Product offeringCore offering
Immedica commercializes proprietary, in-licensed, and acquired pharmaceutical products for rare diseases and specialty care across more than 50 countries in Europe, MENA, and the U.S. Its portfolio spans four therapeutic areas (RARE Metabolic, RARE Hematology & Oncology, RARE Neurology, RARE Endocrinology) plus Specialty Care, marketed under brands such as Loargys, Ztalmy, Efmody, Alkindi, Zepzelca, Ravicti, Ammonaps, Orphacol, Yondelis, Akynzeo, Aloxi, and Neofordex. It also supplies the Nor-NOHA Blood Collection Tubes in vitro diagnostic device supporting Arginase 1 Deficiency diagnosis.
Product overview
Immedica is a Stockholm-headquartered pharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care, supplying patients in more than 50 countries via its own commercial platforms in Europe, MENA, and the U.S. The portfolio is organized around four core therapeutic areas (RARE Metabolic, RARE Hematology & Oncology, RARE Neurology, RARE Endocrinology) plus Specialty Care, and is built through a mix of proprietary, in-licensed, and acquired products rather than a single integrated software platform. Proprietary/lead rare disease assets include Loargys® (pegzilarginase) for Arginase 1 Deficiency, Ztalmy® (ganaxolone) for CDKL5 deficiency disorder, Efmody® (modified-release hydrocortisone) and Alkindi® for adrenal insufficiency/CAH, and Zepzelca® (lurbinectedin) for small cell lung cancer. Supporting/in-licensed products include Ravicti®, Ammonaps®, Orphacol®, Neofordex®, Akynzeo®, Aloxi®, and Yondelis®, complemented by the Nor-NOHA Blood Collection Tubes in vitro diagnostic device and a Specialty Care ophthalmology portfolio. Together these products form a multi-asset rare disease and specialty care franchise rather than a unified single-product offering.
Differentiator
Problem solved
Functional benefit
Products and services
- Loargys (pegzilarginase)
- Ztalmy (ganaxolone)
- Efmody (modified-release hydrocortisone)
- Alkindi (hydrocortisone oral granules)
- Zepzelca (lurbinectedin)
- Ravicti (glycerol phenylbutyrate)
- Ammonaps (sodium phenylbutyrate)
- Orphacol (cholic acid)
- Yondelis (trabectedin)
- Akynzeo (netupitant and palonosetron)
- Aloxi (palonosetron)
- Neofordex (high-dose dexamethasone)
- Nor-NOHA Blood Collection Tubes
Companies that use Immedica
Customer profileNamed customers1 record
Ideal customer profiles3 records
Immedica technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Immedica partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and flagship.
- PharmaMarcoreImmedica has a partnership with PharmaMar for distribution of Zepzelca (lurbinectedin) in various regions. Immedica holds distribution rights for Zepzelca in the Middle East and North Africa (MENA) and other regions. Zepzelca + atezolizumab received positive CHMP opinion as first-line maintenance therapy for extensive-stage small cell lung cancer.
- OrsinicoreOrsini was selected by Immedica Pharma US Inc. as the exclusive specialty pharmacy and hub services partner for LOARGYS (pegzilarginase-nbln), a treatment for hyperargininemia caused by Arginase 1 Deficiency, in the U.S. The partnership involves providing specialty pharmacy, hub, and logistics services to facilitate patient access, including ultra-cold storage at the Columbus, Ohio facility.
- Neurocrine Biosciences (Diurnal Group acquisition)flagshipImmedica completed the acquisition of Neurocrine Group Limited and its subsidiaries from Neurocrine Biosciences for USD 65 million in cash on January 21, 2026. The deal includes global rights to Alkindi (hydrocortisone oral granules) and global rights ex-US to Efmody (hydrocortisone modified-release capsules), establishing rare endocrinology as a new therapeutic area for Immedica.
- OrphanPacificcoreImmedica and OrphanPacific jointly announced approval of Ravicti (glycerol phenylbutyrate) in Japan for the treatment of urea cycle disorders (UCDs). OrphanPacific serves as Immedica's partner for the Japanese market entry.
- Innovative Medicines GroupcoreImmedica and Innovative Medicines Group entered an agreement on Loargys (pegzilarginase) in Latin America. The agreement expands Immedica's reach for Loargys into Latin American markets through IMG's regional distribution capabilities.
- Marinus PharmaceuticalsflagshipImmedica acquired Marinus Pharmaceuticals in a $151 million cash tender offer deal at $0.55 per share. The acquisition brings Ztalmy (ganaxolone), the first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder, into Immedica's portfolio, significantly expanding its US market presence with a revenue-generating commercial product.
- WinHealth PharmacoreImmedica has access to the Chinese market through partnership with the Chinese company WinHealth Pharma. Through this partnership, Immedica helps patients with UCD (Urea Cycle Disorder) in China and surrounding regions.
- Various US and European biotech partnerscoreImmedica has a broad partnering model with US biotech and European companies, executing 16 acquisitions and licensing/distribution agreements since 2018. Their business model is built on partnerships, and they continuously evaluate new business opportunities. They conduct annual partner satisfaction surveys and focus on partnering excellence.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Immedica competitors and assessment
Company assessmentDirect peers
- Jazz Pharmaceuticals: Ireland-headquartered specialty pharmaceutical company focused on rare neurological conditions (epilepsy, narcolepsy) and oncology, with commercial operations across the U.S. and Europe; comparable as a high-growth rare disease specialty pharma with similar in-licensing and acquisition-driven model.
- BioMarin Pharmaceutical: U.S.-based rare disease-focused biotech commercializing enzyme replacement therapies for ultra-rare metabolic disorders (phenylketonuria, MPS, CLN2); highly comparable to Immedica's RARE Metabolic franchise and Loargys positioning, though at significantly larger scale.
- Vertex Pharmaceuticals: Global biotechnology company with a focused rare disease franchise in cystic fibrosis and a growing pipeline in sickle cell disease, beta-thalassemia and pain; comparable as a high-margin specialty pharma with disease-modifying rare disease assets commanding premium pricing.
- Recordati Rare Diseases: Italian specialty pharmaceutical group with a dedicated Recordati Rare Diseases unit commercializing treatments for rare metabolic, endocrine and neurological conditions globally; comparable business model focused on in-licensing and commercializing rare disease assets in Europe and beyond.
- Swedish Orphan Biovitrum (Sobi): Swedish-headquartered rare disease specialty pharmaceutical company focused on hematology, immunology and specialty care, with global commercial infrastructure across Europe, MENA and North America; the most direct comparable to Immedica given shared Swedish heritage, rare disease focus, and similar therapeutic area mix.
- Orphan Europe (Recordati subsidiary): European-focused rare disease subsidiary of Recordati commercializing treatments for metabolic, endocrine and neurological rare diseases across EU and MENA; most operationally comparable to Immedica's European commercial model and target indication mix.
Broad incumbents
- Horizon Therapeutics (Amgen): Ireland-headquartered rare disease specialty pharma (now owned by Amgen) with a focus on rare inflammatory, autoimmune and endocrine diseases (Tepezza, Krystexxa, Ravicti until divestiture); Immedica's Dan Camardo is a former Horizon executive, indicating direct operational and strategic overlap.
- Alexion (AstraZeneca Rare Disease): Acquired by AstraZeneca in 2021, Alexion is a global leader in rare disease specialty pharma (paroxysmal nocturnal hemoglobinuria, hypophosphatasia, neuromyelitis optica) with deep U.S. commercial infrastructure; a broader incumbent against which Immedica competes in the rare hematology/metabolic space.
- Shire (now Takeda Rare Diseases): Pre-acquisition Shire was a global leader in rare disease specialty pharma with franchises in hematology, immunology, GI and neurology; now part of Takeda's Rare Diseases business unit, it represents a broad incumbent whose model of acquiring and commercializing rare disease assets across geographies mirrors Immedica's strategy.
Emerging players
- Ultragenyx Pharmaceutical: U.S.-based clinical-stage and commercial rare disease biotech focused on metabolic diseases, with approved therapies for X-linked hypophosphatemia and other ultrarare conditions; emerging player in the same niche as Immedica's RARE Metabolic franchise (e.g., ARG1-D, urea cycle disorders).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Immedica social profiles
Digital presenceImmedica compliance and trust
Trust signalCompliance3 records
Immedica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immedica leadership team
Management profileNumber of profiles
Profiles14 records
Immedica subsidiaries and ownership
Company hierarchySubsidiaries12 records
Immedica funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immedica M&A and investment
M&A and investmentM&A2 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immedica
What does Immedica do?
Immedica commercializes proprietary, in-licensed, and acquired pharmaceutical products for rare diseases and specialty care across more than 50 countries in Europe, MENA, and the U.S. Its portfolio spans four therapeutic areas (RARE Metabolic, RARE Hematology & Oncology, RARE Neurology, RARE Endocrinology) plus Specialty Care, marketed under brands such as Loargys, Ztalmy, Efmody, Alkindi, Zepzelca, Ravicti, Ammonaps, Orphacol, Yondelis, Akynzeo, Aloxi, and Neofordex. It also supplies the Nor-NOHA Blood Collection Tubes in vitro diagnostic device supporting Arginase 1 Deficiency diagnosis.
Is Immedica a public or private company?
Immedica is a private company. It is classified as private equity controlled and is currently operating.
When was Immedica founded?
Immedica was founded in 2018. It employs 101 to 250 people.
Where is Immedica based?
Immedica is headquartered in Stockholm, Sweden, in the Europe region.
How does Immedica make money?
Three revenue lines are on record. Pharmaceutical Product Sales (Commercialization) is the primary driver. The others are royalty Acquisitions / Royalty Income and in-licensing & Distribution Agreements.
Who are Immedica's main competitors?
Direct peers on record are Jazz Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals, Recordati Rare Diseases, Swedish Orphan Biovitrum (Sobi) and Orphan Europe (Recordati subsidiary). Broad incumbents are Horizon Therapeutics (Amgen), Alexion (AstraZeneca Rare Disease) and Shire (now Takeda Rare Diseases). Ultragenyx Pharmaceutical is listed as an emerging player.
Does Immedica have an API?
No public API is recorded for Immedica.
What industry is Immedica in?
Immedica's product category is Specialty Pharmaceuticals (Rare Disease). Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic), with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 5122.